Michael Yu, Innovent CEO (Anthony Kwan/Bloomberg via Getty Images)

August 16, 2021 06:50 AM EDT

As US review of Eli Lilly-partnered PD-1 gets underway, Innovent touts another frontline win in China

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

Revolution’s KRAS drugs appear competitive in several lung cancer settings

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges